Lilly's Trulicity OK'd; can it top GLP-1 market?
This article was originally published in Scrip
Executive Summary
Watch out Novo Nordisk, GlaxoSmithKline and AstraZeneca.
You may also be interested in...
Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7
Lilly's performance-based plans for Trulicity may be harder to sustain if Novo's competing once-weekly GLP-1 agonist semaglutide is approved in December, following superiority in a head-to-head diabetes study.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.